Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient

Authors

BÍLEK Ondřej HOLÁNEK Miloš JUŘICA Jan ŠTĚPÁNKOVÁ Soňa VAŠINA Jiří SELINGEROVÁ Iveta POPRACH Alexandr BOŘILOVÁ Simona KAZDA Tomáš KISS Igor ZDRAŽILOVÁ DUBSKÁ Lenka

Year of publication 2021
Type Article in Periodical
Magazine / Source International Immunopharmacology
Citation
Web https://www.sciencedirect.com/science/article/pii/S1567576921006482
Doi http://dx.doi.org/10.1016/j.intimp.2021.108012

You are running an old browser version. We recommend updating your browser to its latest version.

More info